Benign Tumor is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Benign Tumor have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Benign Tumor compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Benign Tumor overview
A benign Tumor is also known as non-cancerous. It is not a malignant tumor that does not invade cells or tissues that are nearby. Adenomas, fibromas, hemangiomas, lipomas, myomas, moles are common benign tumors. Exposure to radiation, hereditary factors, diet, and stress are common etiological factors. Benign tumors do not require any treatment but are necessary if symptoms are shown. Surgery is the primary option for removing the non-tumor.
For a complete picture of PTSR and LoA scores for drugs in Benign Tumor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.